Nordic Nanovector to merge with APIM Therapeutics
Nordic Nanovector ASA and all shareholders of APIM Therapeutics ("APIM"), a privately held, clinical-stage cancer-focused biotechnology company, announce that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction
Subject to completion of the Agreement, Nordic Nanovector will purchase shares in APIM, and become the parent entity of APIM. The Agreement follows the review that Nordic Nanovector conducted, in conjunction with Carnegie Investment Bank, to optimise shareholder value following its decision to discontinue the PARADIGME study for Nordic Nanovector's lead asset Betalutin.
Related news and insights
Hillstream BioPharma, Inc, a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, today announced signing an exclusive option agreement with Dana-Farber Cancer Institute to license technology targeting the MUC1-C oncoprotein
Innate Pharma SA announced the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 with respect to the previously announced expansion of its collaboration with Sanofi. The licensing agreement is now effective